petPhealthcare firm Swedencare's Q4 prelim revenue grows 11% organically

Reuters
01/30
petPhealthcare firm Swedencare's Q4 prelim revenue grows 11% organically

Overview

  • Sweden pet healthcare firm's Q4 prelim revenue grew 11% organically to 682 MSEK

  • Profitability impacted by higher marketing costs and operational disruptions

  • Company to complete Amazon transition for NaturVet

Outlook

  • Swedencare plans to complete Amazon transition for NaturVet in 2026

  • Company aims to expand veterinary collaborations in Europe and North America

  • Swedencare expects to normalize margins within Big Box channel

Result Drivers

  • HIGHER MARKETING COSTS - Profitability affected by increased marketing expenses for Amazon and Big Box channel initiatives

  • OPERATIONAL DISRUPTIONS - ERP implementation at NaturVet led to reduced execution speed and delayed shipments

  • BIG BOX CHANNEL INVESTMENTS - Elevated marketing investments to build awareness and support rebranding in Big Box channel

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

SEK 682 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Swedencare AB (publ) is SEK49.00, about 44.3% above its January 29 closing price of SEK33.95

  • The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release: ID:nMFN7YSB6K

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10